Literature DB >> 18555548

The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines.

Theodore Girinsky1, Lena Specht, Mithra Ghalibafian, Veronique Edeline, Guillaume Bonniaud, Richard Van Der Maazen, Berthe Aleman, Amaury Paumier, Paul Meijnders, Yolande Lievens, Evert Noordijk, Philip Poortmans.   

Abstract

PURPOSE: To develop easily applicable guidelines for the determination of initially involved lymph nodes to be included in the radiation fields. PATIENTS AND METHODS: Patients with supra-diaphragmatic Hodgkin lymphoma. All the imaging procedures were carried out with patients in the treatment position. The prechemotherapy PET/CT was coregistered with the postchemotherapy CT simulation for planning purposes. Initially involved lymph nodes were determined on fused prechemotherapy CT and FDG-PET imaging data. The initial assessment was verified with the postchemotherapy CT scan.
RESULTS: The classic guidelines for determining the involvement of lymph nodes were not easily applicable and did not seem to reflect the exact extent of Hodgkin lymphoma. Three simple steps were used to pinpoint involved lymph nodes. First, FDG-PET scans were meticulously analysed to detect lymph nodes that were overlooked on CT imaging. Second, any morphological and/or functional asymmetry was sought on CT and FDG-PET scans. Third, a decrease in size or the disappearance of initially visible lymph nodes on the prechemotherapy CT scan as compared to the postchemotherapy CT scan was considered as surrogate proof of initial involvement.
CONCLUSIONS: All the radiological procedures should be performed on patients in the treatment position for proper coregistration. It is highly advisable that all CT and/or CT/PET scans be performed with IV contrast. Using the above-mentioned three simple guidelines, initially involved lymph nodes can be detected with very satisfactory accuracy. It is also emphasized that the classic guidelines (2, 3, 4) can always be used when deemed necessary.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555548     DOI: 10.1016/j.radonc.2008.05.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Authors:  Gerard Moulin-Romsee; Elif Hindié; Xavier Cuenca; Pauline Brice; Didier Decaudin; Myriam Bénamor; Josette Brière; Marcela Anitei; Jean-Emmanuel Filmont; David Sibon; Eric de Kerviler; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

2.  Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease: a multi-institutional experience.

Authors:  Domenico Genovesi; Giampiero Ausili Cèfaro; Annamaria Vinciguerra; Antonietta Augurio; Monica Di Tommaso; Rita Marchese; Umberto Ricardi; Andrea Riccardo Filippi; Theodore Girinsky; Katiuscia Di Biagio; Maurizio Belfiglio; Enza Barbieri; Vincenzo Valentini
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

Review 3.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

4.  The German evidence-based guidelines for Hodgkin's lymphoma. Aspects for radiation oncologists.

Authors:  H T Eich; J Kriz; H Schmidberger; B Böll; B Klimm; M Rancea; R-P Müller; A Engert
Journal:  Strahlenther Onkol       Date:  2013-04-21       Impact factor: 3.621

5.  Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy.

Authors:  Vedang Murthy; Shirley Lewis; Mayur Sawant; Siji N Paul; Umesh Mahantshetty; Shyam Kishore Shrivastava
Journal:  Technol Cancer Res Treat       Date:  2016-08-19

6.  Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study.

Authors:  C Lütgendorf-Caucig; I Fotina; E Gallop-Evans; L Claude; J Lindh; T Pelz; B Knäusl; D Georg; R Pötter; K Dieckmann
Journal:  Strahlenther Onkol       Date:  2012-10-10       Impact factor: 3.621

7.  Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Chelsea C Pinnix; Sarah A Milgrom; Chan Yoon Cheah; Jillian R Gunther; Ethan B Ludmir; Christine F Wogan; Loretta J Nastoupil; Sattva S Neelapu; Jason Westin; Hun J Lee; Swaminathan P Iyer; Raphael E Steiner; Luis E Fayad; Nathan H Fowler; Michael L Wang; Felipe Samaniego; Maria A Rodriguez; Amy E Rich; L Jeffrey Medeiros; Bouthaina S Dabaja
Journal:  Blood Adv       Date:  2019-05-14

Review 8.  Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.

Authors:  Stephanie A Terezakis; Yvette L Kasamon
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-29       Impact factor: 6.312

9.  Patterns of failure of diffuse large B‑cell lymphoma patients after involved-site radiotherapy.

Authors:  Eva Holzhäuser; Maximilian Berlin; Daniel Wollschläger; Thomas Bezold; Arnulf Mayer; Georg Heß; Heinz Schmidberger
Journal:  Strahlenther Onkol       Date:  2017-07-26       Impact factor: 3.621

10.  A prospective study of ¹⁸FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies.

Authors:  Stephanie A Terezakis; Heiko Schöder; Alexander Kowalski; Patrick McCann; Remy Lim; Alla Turlakov; Mithat Gonen; Chris Barker; Anuj Goenka; Shona Lovie; Joachim Yahalom
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-11       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.